SCHEMBL5875565

SCHEMBL5875565

CCC(O)(CC)c1cnc(N)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ PSEN1 P49768 3/20 0.35
▸ PSEN2 P49810 3/20 0.35
▸ APH1B Q8WW43 3/20 0.35
▸ NCSTN Q92542 3/20 0.35
▸ APH1A Q96BI3 3/20 0.35
▸ PSENEN Q9NZ42 3/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ TSHR P16473 1/20 0.34
▸ POLB P06746 2/20 0.33
▸ MLYCD O95822 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22736793 0.78 NOS1 (0.43) NOS1SMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL3188826 0.78 NOS1 (0.46) NOS1SMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL2988611 0.77 PSEN1 (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5875561 0.77 PSEN1 (0.38) SMN1; SMN2PSEN1PSEN2APH1BNCSTN
SCHEMBL17273952 0.74 SMN1; SMN2 (0.38) NOS1SMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL19261343 0.73 NOS1 (0.38) NOS1SMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL179484 0.73 NOS1 (0.50) NOS1SMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL743585 0.73 NOS1 (0.44) NOS1SMN1; SMN2ALDH1A1MAPTNPC1
Hydrochloric Acid SCHEMBL16416235 0.71 NOS1 (0.43) NOS1SMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL27548506 0.69 NOS1 (0.44) NOS1SMN1; SMN2ALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A — — 2006-02-09 — — JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 — — EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 — — US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 — — WO claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 — — EP disclosed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 — — US disclosed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP NOS1 963/4885SMN1; SMN2 106/4885PSEN1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback